These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19609466)

  • 21. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
    Jekunen A
    Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outsourcing chemical synthesis in the drug discovery process.
    Festel G
    Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech acquisitions by big pharma: why and what is next.
    Malik NN
    Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Creation of a de novo, pharmaceutical company with a urological bent.
    Wyllie MG
    BJU Int; 2011 Nov; 108(9):E310-1. PubMed ID: 22023062
    [No Abstract]   [Full Text] [Related]  

  • 29. Does process excellence handcuff drug development?
    Koenig J
    Drug Discov Today; 2011 May; 16(9-10):377-81. PubMed ID: 21349347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An audience with … Wolfgang Plischke.
    Plischke W; Mullard A
    Nat Rev Drug Discov; 2014 Apr; 13(4):252. PubMed ID: 24687059
    [No Abstract]   [Full Text] [Related]  

  • 31. India's growing clinical research sector: opportunity for global companies.
    Varawalla N
    IDrugs; 2007 Jun; 10(6):391-4. PubMed ID: 17642002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the discovery organization for innovation.
    Sams-Dodd F
    Drug Discov Today; 2005 Aug; 10(15):1049-56. PubMed ID: 16055021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discovery chemistry: a primer for the non-specialist.
    Jordan AM; Roughley SD
    Drug Discov Today; 2009 Aug; 14(15-16):731-44. PubMed ID: 19416759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Creativity, innovation and lean sigma: a controversial combination?
    Johnstone C; Pairaudeau G; Pettersson JA
    Drug Discov Today; 2011 Jan; 16(1-2):50-7. PubMed ID: 21094693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compound management beyond efficiency.
    Burr I; Winchester T; Keighley W; Sewing A
    J Biomol Screen; 2009 Jun; 14(5):485-91. PubMed ID: 19502566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some statistical issues in project prioritization in the pharmaceutical industry.
    Senn S
    Stat Med; 1996 Dec; 15(24):2689-702. PubMed ID: 8981680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug development risk and the cost of capital.
    Baras AI; Baras AS; Schulman KA
    Nat Rev Drug Discov; 2012 Apr; 11(5):347-8. PubMed ID: 22498751
    [No Abstract]   [Full Text] [Related]  

  • 40. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.